Nano4Life 2009 will include speeches by representatives from Glaxosmithkline, the London Centre for Nanotechnology, Astrazeneca, the University of Glasgow and Imperial College London.
This one-day conference and exhibition, organised by the the Nanotechnology Knowledge Transfer Network (NanoKTN) and the Wellcome Trust, will explore key areas in life sciences, where nanotechnology offers the opportunity to advance healthcare provision and improve product discovery and development.
Dr Thomas Keller of Glaxosmithkline (GSK) will address drug delivery aspirations, developments and challenges.
Dr Rachel McKendry from the London Centre for Nanotechnology will examine how nanotechnology has helped shed light on key mechanisms in antibiotic resistance and how it can be applied to drug discovery and development.
McKendry will discuss the ultra-sensitive probes that measure how well a drug binds to bacteria and its ability to target and destroy the bug.
Dr Clive Washington of Astrazeneca will discuss the use of nanotechnology in drug formulation, which is allowing less toxic and better targeted drugs to reach patients.
Professor Jon Cooper from the University of Glasgow will focus on research towards 'lab-on-a-pill' technologies and new micro and nanotechnology tools in healthcare diagnostics.
Professor Molly Stevens from Imperial College will discuss the use of nanotechnology to produce smart materials for use in tissue engineering.
All sectors of the supply chain are encouraged to register for the Nano4Life conference, including research-based pharmacology, biotech and medical device companies, academics, research policy makers and anyone interested in learning about what nanotechnology has to offer the life sciences.
Nano4Life 2009 will take place in London on 11 February.
